<!--
title: Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity
description: DOI: 10.1016/j.etap.2013.04.018
published: true
date: 2022-01-21T13:02:08.673Z
tags: #inflammatory, #treatment, #prevention, #effect, #laboratory, #stress, #sativa, #cardioprotective, #cannabidiol, #cannabis, #invivo, #toxicity, #doxorubicin, #cardiotoxicity, #inflammation, #oxidative, #rats
editor: ckeditor
dateCreated: 2022-01-21T13:02:08.673Z
-->

<p>Environ Toxicol Pharmacol</p>
<p>. 2013 Sep;36(2):347-357.</p>
<p>doi: 10.1016/j.etap.2013.04.018. Epub 2013 May 10.</p>
<h1><strong>Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity</strong></h1>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Fouad+AA&amp;cauthor_id=23721741">Amr A Fouad</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/23721741/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Albuali+WH&amp;cauthor_id=23721741">Waleed H Albuali</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/23721741/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Al-Mulhim+AS&amp;cauthor_id=23721741">Abdulruhman S Al-Mulhim</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/23721741/#affiliation-3"><sup>3</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Jresat+I&amp;cauthor_id=23721741">Iyad Jresat</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/23721741/#affiliation-4"><sup>4</sup></a></p>
<p>Affiliations expand</p>
<ul>
  <li>PMID: <strong>23721741</strong></li>
  <li>DOI: <a href="https://doi.org/10.1016/j.etap.2013.04.018">10.1016/j.etap.2013.04.018</a></li>
</ul>
<h2><strong>Abstract</strong></h2>
<p>The potential protective effect of cannabidiol, the major non-psychotropic Cannabis constituent, was investigated against doxorubicin cardiotoxicity in rats. Cardiotoxicity was induced by six equal doses of doxorubicin (2.5mgkg(-1) i.p., each) given at 48h intervals over two weeks to achieve a total dose of 15mgkg(-1). Cannabidiol treatment (5mgkg(-1)/day, i.p.) was started on the same day of doxorubicin administration and continued for four weeks. Cannabidiol significantly reduced the elevations of serum creatine kinase-MB and troponin T, and cardiac malondialdehyde, tumor necrosis factor-α, nitric oxide and calcium ion levels, and attenuated the decreases in cardiac reduced glutathione, selenium and zinc ions. Histopathological examination showed that cannabidiol ameliorated doxorubicin-induced cardiac injury. Immunohistochemical analysis revealed that cannabidiol significantly reduced the expression of inducible nitric oxide synthase, nuclear factor-κB, Fas ligand and caspase-3, and increased the expression of survivin in cardiac tissue of doxorubicin-treated rats. These results indicate that cannabidiol represents a potential protective agent against doxorubicin cardiac injury.</p>
<p>&nbsp;</p>
<p>Source: https://pubmed.ncbi.nlm.nih.gov/23721741/</p>
